Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study

Documenti analoghi

• Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
  di: Natalia Rompoti, et al.
  Pubblicazione: (2024)
• Dysregulation of epigenetic, biological and mitotic age in the context of biologic drug treatment and phototherapy in plaque psoriasis patients
  di: Richie Jeremian, et al.
  Pubblicazione: (2024)
• Optical coherence tomography‐based imaging biomarkers for disease activity monitoring in plaque psoriasis
  di: L. Ha‐Wissel, et al.
  Pubblicazione: (2024)
• Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
  di: Bruce Strober, et al.
  Pubblicazione: (2024)
• Two cases of cerebrovascular accidents following the induction dose of risankizumab
  di: Algün Polat Ekinci, et al.
  Pubblicazione: (2025)